MSCs have been found to inhibit the growth of CML cells, likely through the production of IFN-α [95] or cytokine-induced neutrophil chemoattractant-1 (CINC-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) [96]. This evidence concerns the gene TIMP1 and chronic myelogenous leukemia, BCR-ABL1 positive.